Endoscopic laser treatment for patients with inoperable oesophageal malignancy may provide reasonable palliation of dysphagia with a low risk of treatment complications.1-3 Especially suitable are patients with short exophytic tumours, non-circumferential tumours, and tumours involving the upper oesophagus where intubation with a prosthesis is difficult.1-3 However, as only intraluminal tumour is treated by the laser, regrowth of tumour into the lumen often occurs and in most series follow up treatment is required at four to eight week intervals to maintain swallowing. 1 Thus while intubation is potentially a one session treatment, laser therapy may need repeating on numerous occasions, particularly in longterm survivors.
In this paper we describe patients who after successful palliation by laser photoablation went on to receive intraluminal radiotherapy as a means of treating extraluminal tumour and mural invasion. Patients were treated with intraluminal radiotherapy if laser palliation was successful, intraluminal tumour recurrence considered likely, and their general condition was good, implying the need for considerable future endoscopic therapy.
Methods
Thirty two patients aged mean (SD) 71 (9) (range 55-83) years received laser therapy and intraluminal radiotherapy. They were considered inoperable principally because of: extensive tumours or metastatic disease (12 with two found to be inoperable at laparotomy); concurrent disease (9) ; or extreme age (9, mean age 78 (5)), and two patients refused surgery. Table I television. The whole procedure takes about two hours. Most patients required an overnight stay in hospital.
The intraluminal radiotherapy was administered one to four weeks after the laser therapy. Those with squamous carcinoma received 10 Gy intraluminally and 30-50 Gy externally in 10 daily fractions. Those with adenocarcinoma received 15 Gy intraluminally only. It was felt that adenocarcinoma was less sensitive to radiotherapy necessitating a higher local dose, and that little additional benefit would accrue to these patients from external radiotherapy. No routine endoscopic follow up was arranged in most cases; patients were encouraged to contact the unit directly if their symptoms recurred.
Results
A median of three (range 1-7) laser treatments were required as an initial treatment to relieve dysphagia. These treatments were complicated by two minor oesophageal perforations comprising a pneumomediastinum with minimal constitutional upset that settled with conservative management. Table II illustrates the effect of the treatment and shows that dysphagia improved in all patients (paired t test p<0.001). After completion of this treatment half of the patients could eat solid food, and all could manage semisolids. The radiotherapy was well tolerated with no complications. Some patients had a minor worsening of their dysphagia, which resolved over a few days.
Overall mean (SEM) survival from diagnosis was 50 (5) weeks with no significant difference between patients with squamous or adenocarcinoma. The mean (SD) requirement for follow up endoscopic therapy was 2.9 (0.9) treatments for patients with adenocarcinoma, and 2.6 (0.6) treatments for patients with squamous cell carcinoma. The Figure shows the outcome of the patients and survival after the selectron therapy.
Almost one third of the patients required no further endoscopic treatment to maintain their swallowing until death. One third required dilatation only, and the remaining third required a combination of dilatation and laser treatment. The development of a fibrous stricture was the commonest cause of recurrent dysphagia occurring in 18 (56%) of patients.
In some cases the stricture occurred within two weeks of the selectron treatment. In these patients dilatation restored swallowing for prolonged intervals. These strictures were sometimes very tough requiring forceful dilatation. In one case dilatation was complicated by oesophageal perforation and death. number of treatment modalities is now available singly or in combination and must be tailored to the individual patient. Laser therapy provides excellent palliation for patients with exophytic tumours particularly when the stricture is short or the tumour is non-circumferential. Some relief of dysphagia is apparent after even one treatment session permitting early discharge from hospital. The main disadvantage of laser therapy is the need for repeat therapy at four to eight week intervals because of regrowth of intraluminal tumour. [1] [2] [3] Intraluminal radiotherapy (brachytherapy) has the advantages of delivering a high radiation dose to the tumour, as a single treatment, with little systemic effect. It may relieve dysphagia in a proportion of patients for several months.4 6 However, in some patients transient worsening of the dysphagia occurs for up to a week after therapy because of tissue oedema.6
It may not therefore be appropriate as a first measure in patients presenting with severe dysphagia, in whom debulking of the tumour with laser therapy provides rapid palliation.
In combining the treatments exophytic tumour was removed by laser and mural invasion treated by radiotherapy. The aim was to achieve rapid effective reliefof dysphagia with laser therapy, and reduce the requirement for follow up laser treatment with intraluminal radiotherapy. This aim was largely achieved as a third of the patients required no further endoscopic therapy at all, and two thirds required a median of three treatmnents over a median survival of 40 weeks after the Selectron treatment.
This combination has been previously used. Bader et al7 used iridium-192 after laser treatment, but six sessions were required over one to two week intervals to permanently relieve the dysphagia. Renwick et al8 used a similar technique to ours but with a rigid oesophagoscope. They also noted a prolonged dysphagia free interval (6 to 
